Emerging medications and pharmacological treatment approaches for substance use disorders☆
Abstract Medications to treat substance use disorders (SUDs) remain suboptimal or, in the case of stimulants and cannabis, non-existent. Many…
Michael T. Bowen
Effects of CB1 receptor negative allosteric modulator Org27569 on oxycodone withdrawal symptoms in mice
Abstract Rationale/Objectives: Targeting cannabinoid receptor type 1 (CB1R) has shown promise for treating opioid withdrawal symptoms. This study aimed to…
Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-FUBINACA, CUMYL-PINACA, PB-22, and XLR-11
Abstract Introduction: Synthetic cannabinoid receptor agonists (SCRAs) are a diverse class of new psychoactive substances that have been associated with…
A nutraceutical product, extracted from Cannabis sativa, modulates voltage-gated sodium channel function
Abstract Background: Purified cannabidiol (CBD), a non-psychoactive phytocannabinoid, has gained regulatory approval to treat intractable childhood epilepsies. Despite this, artisanal…
Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy
Abstract Background and Purpose: Cannabis has been used to treat epilepsy for millennia, with such use validated by regulatory approval…